XML 111 R94.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2018 | Oct. 01, 2017 | Sep. 30, 2018 | Oct. 01, 2017
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [1] | $ 13,298 | $ 13,168 | $ 39,670 | $ 38,843
Innovative Health and Essential Health [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 13,298 | 13,168 | 39,670 | 38,843
Innovative Health and Essential Health [Member] | Lyrica [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [2] | 1,213 | 1,285 | 3,649 | 3,810
Innovative Health and Essential Health [Member] | Viagra [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [3] | 137 | 308 | 509 | 996
Innovative Health and Essential Health [Member] | Alliance revenues [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 977 | 741 | 2,820 | 2,112
Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 8,471 | 8,118 | 24,573 | 23,204
Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [5] | 4,826 | 5,050 | 15,097 | 15,639
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [6] | 2,533 | 2,681 | 7,865 | 7,995
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Lipitor [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 507 | 491 | 1,539 | 1,341
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Norvasc [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 247 | 226 | 773 | 684
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Premarin family [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 204 | 238 | 605 | 711
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xalatan/Xalacom [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 76 | 83 | 233 | 241
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Effexor [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 78 | 76 | 228 | 215
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zoloft [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 72 | 78 | 223 | 215
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zithromax [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 54 | 61 | 216 | 202
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | EpiPen [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 68 | 82 | 215 | 253
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xanax [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 52 | 58 | 163 | 164
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Sildenafil Citrate [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1 | 0 | 72 | 0
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Other Legacy Established Products [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,176 | 1,288 | 3,599 | 3,969
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [7] | 1,239 | 1,273 | 3,928 | 4,270
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Sulperazon [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 145 | 114 | 464 | 345
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Medrol [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 95 | 109 | 318 | 352
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Fragmin [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 76 | 79 | 221 | 221
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Tygacil [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 60 | 60 | 186 | 192
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Tazosyn / Zosyn [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 55 | 47 | 175 | 124
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Precedex [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 47 | 51 | 166 | 182
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | All Other Sterile Injectable Pharmaceuticals [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 761 | 814 | 2,399 | 2,852
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [8] | 698 | 794 | 2,208 | 2,398
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Lyrica [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [2] | 81 | 134 | 251 | 428
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Viagra [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [3] | 137 | 102 | 509 | 285
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Celebrex [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 188 | 212 | 494 | 564
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Vfend [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 87 | 97 | 294 | 305
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Zyvox [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 50 | 68 | 184 | 220
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Revatio [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 53 | 58 | 163 | 189
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Pristiq [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 52 | 69 | 156 | 230
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | All Other Peri-LOE Products [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 49 | 55 | 157 | 176
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [9] | 197 | 141 | 558 | 367
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | Inflectra/Remsima [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 166 | 112 | 469 | 284
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | All Other Biosimilars [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 31 | 28 | 89 | 82
CentreOne [Member] | Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [10] | 159 | 161 | 539 | 514
Hospira Infusion Systems (HIS) [Member] | Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [11] | 0 | 0 | 0 | 97
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 2,463 | 2,455 | 7,339 | 7,245
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Lyrica [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [2] | 1,132 | 1,150 | 3,398 | 3,382
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Eliquis [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 870 | 644 | 2,524 | 1,813
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Chantix / Champix [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 261 | 240 | 789 | 727
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | B M P 2 [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 54 | 79 | 206 | 198
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Toviaz [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 67 | 62 | 197 | 187
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Viagra [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [3] | 0 | 206 | 0 | 711
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | All Other Internal Medicine [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 79 | 75 | 224 | 228
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,845 | 1,649 | 4,708 | 4,385
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | Prevnar 13/Prevenar 13 [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,660 | 1,522 | 4,290 | 4,069
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | FSME-IMMUN/TicoVac [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 57 | 43 | 162 | 119
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | Trumenba [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 61 | 42 | 95 | 79
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | All other Vaccines [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 67 | 43 | 160 | 117
Oncology [Member] | Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,775 | 1,616 | 5,294 | 4,551
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Ibrance [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,025 | 878 | 2,985 | 2,410
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Sutent [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 248 | 276 | 785 | 805
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xtandi Alliance [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 180 | 150 | 510 | 422
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xalkori [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 127 | 146 | 417 | 442
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Inlyta [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 71 | 84 | 226 | 256
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Bosulif [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 69 | 57 | 206 | 163
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | All other Oncology [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 55 | 26 | 164 | 54
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,018 | 1,000 | 2,951 | 2,863
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Enbrel (Outside the U.S. and Canada) [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 531 | 613 | 1,589 | 1,818
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Xeljanz [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 432 | 348 | 1,221 | 935
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Eucrisa [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 40 | 15 | 104 | 33
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | All Other Inflammation and Immunology Products [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 15 | 23 | 37 | 78
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 531 | 569 | 1,651 | 1,637
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | BeneFIX [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 132 | 151 | 420 | 453
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Genotropin [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 143 | 136 | 416 | 375
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | ReFacto AF/ Xyntha [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 117 | 140 | 388 | 409
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Somavert [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 64 | 65 | 195 | 182
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | All Other Rare Disease [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 74 | 77 | 232 | 218
Consumer Healthcare [Member] | Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | $ 839 | $ 829 | $ 2,631 | $ 2,522
[1] | Amounts may not add due to rounding.
[2] | Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.
[3] | Viagra lost exclusivity in the U.S. in December 2017. Beginning in 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, are reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, beginning in 2018, total Viagra revenues are reported in EH. Total Viagra revenues in 2017 represent the aggregate of worldwide revenues from Viagra IH and Viagra EH.
[4] | The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare.
[5] | The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017).
[6] | Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
[7] | Sterile Injectable Pharmaceuticals includes branded and generic injectables (excluding Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
[8] | Peri-LOE Products includes products that have recently lost or are anticipated to soon lose patent protection. These products primarily include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra; and beginning in 2018, Viagra revenues for all countries (and Viagra revenues for all countries other than the U.S. and Canada in 2017, see note (c) above).
[9] | Biosimilars includes Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and in the U.S. and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets.
[10] | Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
[11] | HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthandEssentialHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_LyricaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ViagraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllianceBiopharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_DistinctBusinessAxis=pfe_InnovativeHealthBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_DistinctBusinessAxis=pfe_EssentialHealthBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_LipitorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_NorvascMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PremarinFamilyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XalatanXalacomMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EffexorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZoloftMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EpiPenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XanaxXanaxXRMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SildenafilCitrateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherLegacyEstablishedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_SterileInjectablePharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SulperazonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_MedrolMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_FragminMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TygacilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZosynTazocinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PrecedexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherSterileInjectablePharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_CelebrexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_VfendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZyvoxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_RevatioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PristiqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherPeriLOEProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_BiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_InflectraRemsimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherBiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_CentreOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_HospiraInfusionSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_InternalMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ChantixChampixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BMP2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ToviazMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_VaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TrumenbaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_IbranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SutentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XtandiAllianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XalkoriMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_InlytaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BosulifMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_InflammationandImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EnbrelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XeljanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EucrisaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_RareDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BeneFIXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_GenotropinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SomavertMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_ConsumerHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |